Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure

British Journal of Pharmacology

Volumn 162, Issue 3, 2011, Pages 566-573

  Van Hees, H W H ^a   Andrade Acuna G L ^a   Linkels, M ^a   Dekhuijzen, P N R ^a   Heunks, L M A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

calcium sensitization; heart failure; respiratory muscle; skinned fibres

Indexed keywords

CALCIUM; DIMETHYL SULFOXIDE; LEVOSIMENDAN; MYOSIN HEAVY CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIAPHRAGM MUSCLE; DISEASE MODEL; HEART FAILURE; MALE; MUSCLE CELL; MUSCLE FIBER CONTRACTION; MUSCLE FORCE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM; DIAPHRAGM; HEART FAILURE; HUMANS; HYDRAZONES; MALE; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCLE WEAKNESS; MYOSIN HEAVY CHAINS; PYRIDAZINES; RATS; RATS, WISTAR;

EID: 78651421808     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01048.x     Document Type: Article

References (42)

1. Al-Rawas OA, Carter R, Richens D, Stevenson RD, Naik SK, Tweddel A, et al. (1995). Ventilatory and gas exchange abnormalities on exercise in chronic heart failure. Eur Respir J 8: 2022-2028.
2. Antila S, Sundberg S, Lehtonen LA, (2007). Clinical pharmacology of levosimendan. Clin Pharmacokinet 46: 535-552.
3. 2+ cycling in skeletal muscle. J Muscle Res Cell Motil 28: 259-274.
4. Brenner B, (1983). Technique for stabilizing the striation pattern in maximally calcium-activated skinned rabbit psoas fibers. Biophys J 41: 99-102.
5. Brenner B, (1998). Muscle mechanics II: skinned muscle fibers. In:, Sugi H, (ed.). Current Methods In Muscle Physiology. Oxford University Press: Oxford, pp. 33-69.
6. Burkholder TJ, Lieber RL, (2001). Sarcomere length operating range of vertebrate muscles during movement. J Exp Biol 204: 1529-1536.
7. Carmo MM, Barbara C, Ferreira T, Branco J, Ferreira S, Rendas AB, (2001). Diaphragmatic function in patients with chronic left ventricular failure. Pathophysiology 8: 55-60. (Pubitemid 32703773)
8. Chua TP, Anker SD, Harrington D, Coats AJ, (1995). Inspiratory muscle strength is a determinant of maximum oxygen consumption in chronic heart failure. Br Heart J 74: 381-385.
9. Collett PW, Perry C, Engel LA, (1985). Pressure-time product, flow, and oxygen cost of resistive breathing in humans. J Appl Physiol 58: 1263-1272.
10. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107-113.
11. Faggiano P, d'Aloia A, Gualeni A, Giordano A, (2001). Relative contribution of resting haemodynamic profile and lung function to exercise tolerance in male patients with chronic heart failure. Heart 85: 179-184.
12. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. (2002). Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360: 196-202.
13. Geiger PC, Cody MJ, Sieck GC, (1999). Force-calcium relationship depends on myosin heavy chain and troponin isoforms in rat diaphragm muscle fibers. J Appl Physiol 87: 1894-1900.
14. Geiger PC, Cody MJ, Macken RL, Sieck GC, (2000). Maximum specific force depends on myosin heavy chain content in rat diaphragm muscle fibers. J Appl Physiol 89: 695-703.
15. van Hees HW, van der Heijden HF, Ottenheijm CA, Heunks LM, Pigmans CJ, Verheugt FW, et al. (2007). Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats. Am J Physiol Heart Circ Physiol 293: H819-H828.
16. van Hees HW, Dekhuijzen PN, Heunks LM, (2009). Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 179: 41-47.
17. Hughes PD, Polkey MI, Harrus ML, Coats AJ, Moxham J, Green M, (1999). Diaphragm strength in chronic heart failure. Am J Respir Crit Care Med 160: 529-534.
18. Kaheinen P, Pollesello P, Levijoki J, Haikala H, (2004). Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 43: 555-561.
19. Kivikko M, Lehtonen L, Colucci WS, (2003). Sustained hemodynamic effects of intravenous levosimendan. Circulation 107: 81-86.
20. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, et al. (2000). Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 101: 2803-2809.
21. Kurotobi T, Sato H, Yokoyama H, Li D, Koretsune Y, Ohnishi Y, et al. (1997). Respiratory oxygen cost for dead space challenge is characteristically increased during exercise in patients with chronic heart failure: does it further decrease exercise capacity? J Card Fail 3: 181-188.
22. 2+ handling in skeletal muscle during fatigue. Circ Res 98: 1514-1519.
23. McParland C, Krishnan B, Wang Y, Gallagher CG, (1992). Inspiratory muscle weakness and dyspnea in chronic heart failure. Am Rev Respir Dis 146: 467-472.
24. Mancini DM, Henson D, LaManca J, Levine S, (1992). Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation 86: 909-918.
25. Meyer FJ, Zugck C, Haass M, Otterspoor L, Strasser RH, Kubler W, et al. (2000). Inefficient ventilation and reduced respiratory muscle capacity in congestive heart failure. Basic Res Cardiol 95: 333-342.
26. Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kubler W, et al. (2001). Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 103: 2153-2158.
27. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. (2005). Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 111: 1504-1509.
28. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. (2002). Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23: 1422-1432.
29. Moxham J, Jolley C, (2009). Breathlessness, fatigue and the respiratory muscles. Clin Med 9: 448-452.
30. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. (2000). Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36: 1903-1912.
31. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, et al. (1979). Myocardial infarct size and ventricular function in rats. Circ Res 44: 503-512.
32. Roher A, Lieska N, Spitz W, (1986). The amino acid sequence of human cardiac troponin-C. Muscle Nerve 9: 73-77.
33. Sorsa T, Pollesello P, Permi P, Drakenberg T, Kilpelainen I, (2003). Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol 35: 1055-1061.
34. Sorsa T, Pollesello P, Solaro RJ, (2004). The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem 266: 87-107.
35. Sweeney HL, Corteselli SA, Kushmerick MJ, (1987). Measurements on permeabilized skeletal muscle fibers during continuous activation. Am J Physiol 252: C575-C580.
36. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, et al. (2004). The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 486: 67-74.
37. Szilagyi S, Pollesello P, Levijoki J, Haikala H, Bak I, Tosaki A, et al. (2005). Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol 46: 369-376.
38. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, et al. (1997). Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 61: 596-607.
39. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. (2000). Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68: 522-531.
40. Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koike A, Lubarsky L, et al. (1997). Lung function and exercise gas exchange in chronic heart failure. Circulation 96: 2221-2227. (Pubitemid 27425826)
41. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N, (1997). The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375-383.
42. Zuurbier CJ, Heslinga JW, Lee-de Groot MB, van der Laarse WJ, (1995). Mean sarcomere length-force relationship of rat muscle fibre bundles. J Biomech 28: 83-87.